CG
NVO

Cutler Group’s Novo Nordisk NVO Stock Holding History

Cutler Group’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,000
Closed -$7K – 3183
2023
Q4 		$7K Buy
+3,000
New +$297K ﹤0.01% 2581
2022
Q2 		– Sell
-600
Closed -$2K – 5455
2022
Q1 		$2K Buy
+600
New +$30.8K ﹤0.01% 4719
2018
Q2 		– Sell
-12,800
Closed -$3K – 4657
2018
Q1 		$3K Buy
+12,800
New +$336K ﹤0.01% 3588
2017
Q4 		– Sell
-64,200
Closed -$156K – 5596
2017
Q3 		$156K Sell
64,200
-65,800
-51% -$1.49M 0.01% 1337
2017
Q2 		$192K Buy
+130,000
New +$2.62M 0.01% 1318
2016
Q3 		– Sell
-8,200
Closed -$5K – 7163
2016
Q2 		$5K Buy
8,200
+400
+5% +$11K ﹤0.01% 4952
2016
Q1 		$9K Sell
7,800
-1,600
-17% -$42.9K ﹤0.01% 4180
2015
Q4 		$6K Buy
+9,400
New +$260K ﹤0.01% 4722

Other funds holding NVO

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $42.5B AUM 18.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Cutler Group's NVO Position: Q1 2024 in Review

Cutler Group sold out of Novo Nordisk (NVO) in Q1 2024, closing a stake of 3,076 shares — an estimated $318K sold.

Cutler Group first reported a position in NVO in Q1 2016 and held it in 9 quarters. The position peaked at $786K in Q3 2017. 1,747 funds tracked by Wall St. Rank hold NVO as of Q1 2024.

  • Cutler Group reported no remaining Novo Nordisk position as of Q1 2024 after selling out during the quarter.
  • Cutler Group sold 3,076 Novo Nordisk shares in Q1 2024, an estimated $318K.
  • Cutler Group first reported a position in Novo Nordisk in Q1 2016 and held it in 9 quarters.
  • Cutler Group's Novo Nordisk position peaked at $786K in Q3 2017.
  • 1,747 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.